MedTrace Logo

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration

NCT01736592 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-06-12

No results posted yet for this study

Summary

Primary Objective:

To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's Macular Degeneration.

Secondary Objective:

To assess:

* Safety
* Biological activity

Conditions

  • Stargardt's Disease

Interventions

DRUG

Long term follow up in all patients who received SAR422459 in previous study TDU13583

Blood draw for the laboratory assessment

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-14
Primary Completion
2033-08-29
Completion
2033-08-29
FDA Drug
Yes

Countries

  • United States
  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01736592 on ClinicalTrials.gov